Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v2.4.0.8
BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash $ 11,798 $ 18,102
Receivables 4,818 4,646
Prepaid expenses and other current assets 204 687
Total current assets 16,820 23,435
Property and equipment, net 1,603 1,392
Total Assets 18,423 24,827
Current liabilities:    
Accounts payable 5,118 3,767
Accrued clinical trials expenses 118 532
Other accrued liabilities 293 219
Deferred contract revenue 5,317 14,375
Current portion of long-term debt 0 2,500
Total current liabilities 10,846 21,393
Warrant liability 1,817 8,240
Royalty liability 0 8,962
Long-term debt, net of discount 0 9,360
Total Liabilities 12,663 47,955
Commitments and contingencies      
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2013 and 2012. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized, 88,794,222 and 75,215,713 shares issued and outstanding at December 31, 2013 and 2012, respectively. 284,485 265,986
Additional paid-in capital 21,692 21,014
Accumulated deficit (300,417) (310,128)
Total stockholders’ equity (deficit) 5,760 (23,128)
Total Liabilities and Stockholders’ Equity (Deficit) $ 18,423 $ 24,827